Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)
The results indicate that patients with advanced non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia could be effectively and safely treated using a combination of CBDCA, PXT and Bmab.
Authors
- Kazuma Nagata (ORCID: https://orcid.org/0000-0001-9980-2086)
- Motohiro Tamiya (ORCID: https://orcid.org/0000-0001-6529-3092)
- Toshihiko Kaneda
- Takaaki Tokito (ORCID: https://orcid.org/0000-0002-8429-2287)
- Yukimasa Hatachi
- Satoshi Morita (ORCID: https://orcid.org/0000-0002-4344-3317)
- Masahide Oki (ORCID: https://orcid.org/0000-0001-6302-4534)
- Akiyoshi Nakakura
- Tadashi Okamoto
- Nobuyuki Katakami
- Kana Watanabe (ORCID: https://orcid.org/0000-0001-5139-5901)
- Yoshihiro Amano
Institutions
- Kurume University (JP)
- Shimane University (JP)
- Kyoto University (JP)
- Osaka Prefectural Medical Center (JP)
- Kurashiki Central Hospital (JP)
- Miyagi Prefectural Hospital Organization (JP)
- National Hospital Organization (JP)
- Nagoya Medical Center (JP)
- Takarazuka City Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1093/jjco/hyae132
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00